The Cancer Letter

Inside information on cancer research and drug development

In Brief

Steven Lemery named acting associate director of Tissue Agnostic Drug Development at FDA’s OCE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Steven Lemery was named acting associate director of Tissue Agnostic Drug Development within FDA’s Oncology Center of Excellence.

Lemery will continue as division director for the Division of Oncology 3.

Lemery joined FDA in 2006 as a clinical reviewer in the Division of Biological Oncology Products, which ultimately re-organized into the Division of Oncology Products 2. He served as team lead on the Gastrointestinal Malignancies team in the Division of Oncology Products 2 where he supervised the review of multiple original and supplemental applications.

Subsequently, he assumed the role of the supervisory associate division director in DOP2, primarily leading activities for the melanoma/sarcoma and pediatrics/rare malignancies teams.

More recently, he has assumed the role of acting director of DO3 and is a member of the Medical Policy and Program Review Council. In various roles, he has contributed to Office- and OCE-led regulatory or policy initiatives. These have included both biosimilar development and tissue agnostic development.

In his new role in the OCE, Lemery will focus on scientific and policy efforts related to tissue agnostic drug development and lead outreach and education in this topic.

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
By Claire Marie Porter
Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
By Ze’ev Ronai
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account